Table 2

Primary care patient baseline characteristics

VariableMean, SD
Age65.4, 10.9
n, %
Sex
 Female9, 50.0%
 Male9, 50.0%
Race
 Black or African American10, 55.6%
 White0, 0%
 Asian0, 0%
 Other, unspecified5, 27.8%
 Decline or unavailable3, 16.7%
Ethnicity
 Hispanic or Latino6, 33.3%
 Non-Hispanic10, 55.6%
 Decline or unavailable2, 11.1%
HbA1c
 At goal ≤ 78, 44.4%
 Not at goal10, 55.6%
Blood pressure
 At goal ≤130/805, 27.8%
 Not at goal13, 72.2%
eGFR categories
 Category 1, eGFR ≥903, 16.7%
 Category 2, eGFR 60–899, 50.0%
 Category 3, eGFR 30–595, 26.3%
 Category 4, eGFR <301, 5.6%
Degree of proteinuria
 Moderate proteinuria6, 33.3%
 Severe proteinuria12, 66.7%
Count of diabetes-related prescriptions*
 01, 5.6%
 19, 50.0%
 23, 16.7%
 33, 16.7%
 42, 11.1%
Count of hypertension-related prescriptions †
 06, 33.3%
 17, 38.9%
 23, 16.7%
 31, 5.6%
 41, 5.6%
Insurance type
 Medicaid3, 16.7%
 Medicare10, 55.6%
 Commercial5, 27.8%
 Uninsured0, 0%
  • *Count of prescriptions in EHR-defined pharmaceutical classes: insulins, biguanides, glucagon-like peptide 1 (GLP-1) agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, sulfonylureas, thiazolidinediones, and alpha-glucosidase inhibitors; excludes SGLT2i prescription.

  • †Count of prescriptions in EHR-defined pharmaceutical classes: thiazide, loop and potassium-sparing diuretics, beta-blockers, calcium channel blockers, combined alpha and beta-blockers, alpha-antagonists, and hydralazine; excludes RAASi prescription.

  • eGFR, estimated glomerular filtration rate; EHR, electronic health record; GFR, glomerular filtration rate; HbA1C, hemoglobin A1C; RAASi, renin–angiotensin–aldosterone system inhibitors; SGLT2i, sodium-glucose cotransporter-2 inhibitors.